SCHEDULE: Frazier Life Sciences Amends Macrogenics Stake

Frazier Life Sciences group files an amended Schedule 13G, clarifying its beneficial ownership in Macrogenics, Inc. to 5.1% of common stock.

Summary

• Frazier Life Sciences Public Fund, L.P. and its related entities reported shared beneficial ownership of 1,549,193 shares, representing 2.5% of Macrogenics, Inc. Common Stock.
• Frazier Life Sciences Public Overage Fund, L.P. and its related entities reported shared beneficial ownership of 925,809 shares, representing 1.5% of Macrogenics, Inc. Common Stock.
• Frazier Life Sciences X, L.P. and its related entities, including James N. Topper and Patrick J. Heron, reported shared beneficial ownership of 125,513 shares, representing 0.2% of Macrogenics, Inc. Common Stock.
• Frazier Life Sciences XI, L.P. and its related entities reported shared beneficial ownership of 575,150 shares, representing 0.9% of Macrogenics, Inc. Common Stock.
• The aggregate beneficial ownership by the Frazier Life Sciences group totals 3,175,665 shares, representing approximately 5.1% of the outstanding common stock.
• The filing is an amendment to correct previous attribution and overstatement of beneficial ownership by certain members of the investment committees.
• The beneficial ownership percentages are calculated based on 63,090,323 shares of Common Stock outstanding as of May 9, 2025, as reported in Macrogenics' Form 10-Q filed on May 13, 2025.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Macrogenics, Inc.

Sentiment

Score: 5

Explanation: The filing is a standard compliance update (Schedule 13G Amendment) clarifying beneficial ownership. It does not contain new financial results, strategic announcements, or operational updates that would typically influence sentiment positively or negatively. The stated purpose is to correct previous attribution, indicating an administrative adjustment rather than a market-moving event.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor group in a biotechnology company. Such disclosures are common and provide transparency regarding significant shareholder stakes, which can be relevant for understanding the investor base of a company in the highly capital-intensive biotechnology sector.

Stakeholder Impact

• Shareholders: Provides clarity on the beneficial ownership structure of a significant institutional investor group, ensuring transparency regarding who holds voting and dispositive power over a portion of the company's stock.

Key Dates

Keywords

Macrogenics, Frazier Life Sciences, Biotechnology, Pharmaceuticals, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Schedule 13G